For the quarter ending 2025-09-30, ANAB had $65,535K increase in cash & cash equivalents over the period. -$27,368K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 15,113 | -77,959 |
| Depreciation and amortization | 140 | 288 |
| Stock-based compensation | 9,157 | 18,409 |
| Accretion/amortization of investments, net | 1,130 | 3,264 |
| Amortization of right-of-use assets operating | 470 | 919 |
| Non-cash interest expense | -22,515 | -37,667 |
| Receivables from collaborative partners | 54,267 | -19,347 |
| Prepaid expenses and other assets | 303 | -944 |
| Accounts payable and other liabilities | -18,561 | -46,354 |
| Operating lease liabilities | -490 | -941 |
| Net cash used in operating activities | -27,356 | -50,944 |
| Purchases of investments | 19,656 | 176,755 |
| Sales and maturities of investments | 122,950 | 228,079 |
| Purchases of property and equipment | 12 | 74 |
| Net cash provided by investing activities | 103,282 | 51,250 |
| Proceeds from public offerings, net of underwriters fees | 0 | - |
| Proceeds from issuance of common stock | 336 | 1,713 |
| Repurchase and retirements of common stock | 9,720 | 55,522 |
| Proceeds from the sale of future royalties | 0 | 0 |
| Payment for net share settlement of equity awards | 0 | 1,451 |
| Principal repayment of liability for sale of future royalties | 1,007 | 23,828 |
| Payments for offering costs | 0 | - |
| Payments for debt issuance costs | 0 | 0 |
| Net cash (used in) provided by financing activities | -10,391 | -79,088 |
| Net (decrease) increase in cash and cash equivalents | 65,535 | -78,782 |
| Cash and cash equivalents at beginning of period | 123,080 | - |
| Cash and cash equivalents at end of period | 109,833 | - |
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)